32 active not recruiting. 32 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 32 | Active not recruiting 32 |
| Phase 2 | 4 | Active not recruiting 4 |
Follow Demyelinating Diseases: new trials by email Literature Review of Demyelinating Diseases trials Research Report on Demyelinating Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD eculizumab - NMOSD, Neuromyelitis Optica Spectrum Disorders | Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 21 | 2025-01-16 | 2025-12-19 |
| Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) Ocrelizumab (US), Ocrelizumab (EU), ABP 692 - Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 3 | Active not recruiting | Amgen | 152 | 2025-01-13 | 2026-09-22 |
| A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work Riliprubart, Placebo - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic | Phase 3 | Active not recruiting | Sanofi | 109 | 2024-07-12 | 2026-08-10 |
| A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. Tolebrutinib, Placebo, Teriflunomide - Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | Phase 3 | Active not recruiting | Sanofi | 2500 | 2024-04-16 | 2026-08-17 |
| Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis Frexalimab, Placebo, MRI contrast-enhancing agents - Multiple Sclerosis | Phase 3 | Active not recruiting | Sanofi | 943 | 2023-12-27 | 2026-05-14 |
| Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis Frexalimab, Teriflunomide, Placebo infusion - Multiple Sclerosis | Phase 3 | Active not recruiting | Sanofi | 1655 | 2023-12-13 | 2026-07-20 |
| Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial Ocrelizumab Injection [Ocrevus] - Multiple Sclerosis | Phase 3 | Active not recruiting | Fondation Ophtalmologique Adolphe de Rothschild | 244 | 2023-11-09 | 2026-08-28 |
| Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE) divozilimab - Neuromyelitis Optica Spectrum Disorders | Phase 3 | Active not recruiting | Biocad | 105 | 2022-12-12 | 2024-11-07 |
| Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders Daratumumab, Placebo - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 2 / Phase 3 | Active not recruiting | Tianjin Medical University General Hospital | 135 | 2022-11-01 | 2025-03-30 |
| A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) MIL62, Placebo - Neuromyelitis Optica Spectrum Disorder | Phase 3 | Active not recruiting | Beijing Mabworks Biotech Co., Ltd. | 102 | 2022-08-18 | 2025-09-25 |
| Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD Ravulizumab - Neuromyelitis Optica Spectrum Disorder | Phase 2 / Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 12 | 2022-06-23 | 2026-06-24 |
| A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) Ocrelizumab, Ocrelizumab Placebo, Fingolimod - Relapsing-remitting Multiple Sclerosis | Phase 3 | Active not recruiting | Hoffmann-La Roche | 188 | 2022-05-19 | 2026-07-15 |
| A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis Ocrelizumab - Multiple Sclerosis | Phase 3 | Active not recruiting | Hoffmann-La Roche | 1300 | 2022-05-03 | 2026-10-28 |
| LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB Ocrelizumab - Multiple Sclerosis | Phase 3 | Active not recruiting | Centre Hospitalier Universitaire de Nice | 72 | 2022-03-08 | 2024-05-17 |
| OTL-200 in Patients With Late Juvenile Metachromatic Leukodystrophy (MLD) OTL-200 - Lysosomal Storage Diseases, Metachromatic Leukodystrophy | Phase 3 | Active not recruiting | Orchard Therapeutics | 6 | 2022-01-17 | 2025-09-05 |
| Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis IMU-838 tablets, Placebo matching IMU-838 tablets - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Active not recruiting | Immunic AG | 1100 | 2022-01-12 | 2026-10-01 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis IMU-838 tablets, Placebo matching IMU-838 tablets - Multiple Sclerosis | Phase 3 | Active not recruiting | Immunic AG | 1121 | 2021-11-18 | 2026-10-01 |
| Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis Fingolimod, Ofatumumab, Siponimod - Multiple Sclerosis (MS) | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 129 | 2021-10-05 | 2026-05-14 |
| ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis Cladribine (MAVENCLAD®), Placebo - Advanced Multiple Sclerosis, Progressive Multiple Sclerosis | Phase 2 / Phase 3 | Active not recruiting | Queen Mary University of London | 204 | 2021-06-25 | 2026-09-08 |
| A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD) zilganersen, Placebo - Alexander Disease | Phase 3 | Active not recruiting | Ionis Pharmaceuticals, Inc. | 54 | 2021-06-01 | 2026-08-21 |
Showing 20 of 32. Sign in to see all of them.
Multiple Sclerosis (14) · Multiple Sclerosis, Chronic Progressive (7) · Multiple Sclerosis, Relapsing-Remitting (7) · Neuromyelitis Optica (5) · Alexander Disease (1) · Autoimmune Diseases of the Nervous System (1) · Charcot-Marie-Tooth disease, Type 1F (1) · Leukodystrophy, Metachromatic (1) · Lysosomal Storage Diseases (1) · Nervous System Diseases (1) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (1) · Recurrence (1) · Thinness (1)
Nervous System Diseases (31) · Autoimmune Diseases (30) · Immune System Diseases (30) · Autoimmune Diseases of the Nervous System (29) · Demyelinating Autoimmune Diseases, CNS (29) · Multiple Sclerosis (10) · Pathological Conditions, Signs and Symptoms (10) · Disease Attributes (9) · Pathologic Processes (9) · Chronic Disease (8) · Cranial Nerve Diseases (5) · Eye Diseases (5) · Myelitis, Transverse (5) · Optic Nerve Diseases (5)
ocrelizumab (13) · Fingolimod Hydrochloride (3) · Methylprednisolone (3) · Cladribine (2) · Histamine Antagonists (2) · Interferon beta-1a (2) · Rituximab (2) · teriflunomide (2) · Acetaminophen (1) · Alemtuzumab (1) · Charcoal (1) · Cholestyramine Resin (1) · Cyclophosphamide (1) · SLI381 (1) · daratumumab (1)
Hoffmann-La Roche (7) · Sanofi (4) · Alexion Pharmaceuticals, Inc. (2) · Haukeland University Hospital (2) · Immunic AG (2) · Novartis Pharmaceuticals (2) · Amgen (1) · Beijing Mabworks Biotech Co., Ltd. (1) · Biocad (1) · Biogen (1) · Centre Hospitalier Universitaire de Nice (1) · Copenhagen University Hospital, Rigshospitalet (1) · Fondation Ophtalmologique Adolphe de Rothschild (1) · Ionis Pharmaceuticals, Inc. (1) · Orchard Therapeutics (1)
France (19) · United States (19) · Italy (18) · Canada (17) · Germany (16) · Poland (16) · Spain (16) · Turkey (Türkiye) (13) · Ukraine (13) · United Kingdom (13) · Belgium (12) · Brazil (12) · Bulgaria (12) · Mexico (12) · Portugal (12)
Robert J. Fox, MD (2) · Anne Kristine Lehmann, MD, PhD (1) · Astrid Kittang, MD, PhD (1)
PMID 42208560, PMID 30207920, PMID 31467033, PMID 39812825, PMID 39899371, PMID 40258203, PMID 41933619, PMID 42177718, PMID 42208561, PMID 42384870, PMID 42546561, PMID 42575985, PMID 42663866
2023 (10), 2018 (3), 2017 (2), 2019 (1)